米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床效果及安全性

目的:探讨米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床效果及安全性。方法:选择2012年6月—2014年6月我院接诊的60例子宫肌瘤患者进行研究,随机分为观察组和对照组。观察组30例,采用米非司酮联合血府逐瘀胶囊治疗。对照组30例,采用米非司酮。比较两组患者的子宫体积及子宫肌瘤的体积、激素含量(LH、FSH、P、E2)、治疗效果及不良反应(恶心,头痛,乏力)。结果:治疗后,观察组患者与对照组患者子宫的体积相比有统计学差异,观察组小于对照组(t=9.3029,P=0.0003);观察组患者的子宫肌瘤的体积小于对照组患者,两者相比有统计学差异(t=3.8804,P<0.0001);观察组患者的LH、FSH、P、E2含量均小于对照组患者,两者相比有统计学差异(P<0.05);观察组的治疗效果优于对照组,两者相比有统计学差异(u=2.4591,P=0.0139);不良反应比较中,观察组与对照组的术后头痛发生比率为0.00%和13.33%,两者相比有统计学差异(χ2=4.2857,P=0.0384);观察组与对照组的不良反应总的发生比率为6.67%和36.67%,两者相比有统计学差异(χ2=7.9542,P=0.0048)。结论:米非司酮联合血府逐瘀胶囊治疗子宫肌瘤的临床疗效良好,安全性较高,预后良好,值得临床推广。

Clinical Effect and Safety of Mifepristone with Xuefu Zhuyu Jiaonang for Uterine Fibroids

Objective: To investigate the clinical effect and safety of mifepristone with Xuefu Zhuyu Jiaonang for uterine fibroids. Methods: 60 patients with uterine fibroids from June 2012 to June 2014 in our hospital were researched. They were divided randomly into observation and control groups. The observation group had 30 patients,who were treated by using mifepristone with Xuefu Zhuyu Jiaonang. Control group had 30 patients,using Xuefu Zhuyu Jiaonang. And then we compared the volume of the uterus and uterine fibroids volume in two groups,the hormone content( LH,FSH,P,E2),the therapeutic effect and adverse reactions( nausea,headache,fatigue). Results: After treatment,uterine volume in the observation group was smaller than that of the control group and there was a significant difference( t = 9. 3029,P = 0. 0003). The uterine fibroids volume in the observation group was smaller than that of the control group and there was a significant difference( t = 3. 8804,P < 0. 0001). The contents of LH,FSH,P and E2 of the patients in the observation group were less than those of control group's patients and there were statistically significant difference( P < 0. 05). The observation group's effect was better than that of the control group and there was a significant differences( u = 2. 4591,P = 0. 0139). The headache ratios in the observation group and the control group were 0. 00% and 13.33% and there was a significant difference( χ2= 4. 2857,P = 0. 0384). The overall incidence rates of adverse reactions in the observation group and the control group were 6. 67% and 36. 67% and there was a statistically significant difference( χ2= 7.9542,P = 0. 0048). Conclusion: The clinical efficacy and the prognosis for uterine fibroids by mifepristone with Xuefu Zhuyu Jiaonang is well. It is worthy of promotion in clinic.